ArticleFrontiers in oncology2026
Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. While the R-CHOP regimen achieves a 70% 5-year survival rate, patients with refractory or relapsed disease face poor prognoses. Therefore, it is very important to search for markers related to curative effect and prognosis, and to explore new targeted therapies. Protein kinase C delta (PKCδ), a serine/threonine kinase involved in cell proliferation, growth, and cancer progression, has been proposed as a prognostic marker in solid tumors, but its role in DLBCL remains underexplored. This study aimed to validate PKCδ as a prognostic biomarker and investigate its mechanistic contributions to therapeutic resistance. Methods: Immunohistochemistry (IHC) was used to analyze the expression of PKCδ in 200 DLBCL tissues to validate the correlation between PKCδ and therapeutic efficacy as well as prognosis. Using the DB and RIVA cell lines to stably knock down the PRKCD gene, we explored the role of PKCδ in cell proliferation, cell cycle, apoptosis, chemoresistance, and related signaling pathways through CCK-8 assays, flow cytometry, RNA sequencing, and in vivo xenograft models in nude mice. Additionally, we evaluated the therapeutic efficacy of the multi-kinase inhibitor Rottlerin both in vitro and in vivo. Results: High PKCδ expression correlated with reduced 5-year progression-free survival and overall survival. Knockout of PKCδ repressed DLBCL cell proliferation, facilitated cell cycle arrest in the G2/M phase, induced apoptosis in vitro, and inhibited tumor growth in vivo, and enhanced sensitivity to rituximab and chemotherapeutics. Similarly, inhibition with the multi-kinase inhibitor Rottlerin also impaired tumor growth and showed combinatory efficacy with rituximab. RNA-seq revealed 2,988 differentially expressed genes enriched in AKT, MAPK, and NF-κB signaling pathways. Discussion: Our findings highlight PKCδ as a potential predictive biomarker and therapeutic target. However, due to the off-target effects of Rottlerin, the observed in vivo efficacy and synergistic effects of Rottlerin should be considered as preliminary pharmacological support for the concept of targeting PKCδ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.